Literature DB >> 7692009

Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.

M F Beal1, E Brouillet, B G Jenkins, R J Ferrante, N W Kowall, J M Miller, E Storey, R Srivastava, B R Rosen, B T Hyman.   

Abstract

An impairment of energy metabolism may underlie slow excitotoxic neuronal death in neurodegenerative diseases. We therefore examined the effects of intrastriatal, subacute systemic, or chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid (3-NP) in rats. Following intrastriatal injection 3-NP produced dose-dependent striatal lesions. Neurochemical and histologic evaluation showed that markers of both spiny projection neurons (GABA, substance P, calbindin) and aspiny interneurons (somatostatin, neuropeptide Y, NADPH-diaphorase) were equally affected. Subacute systemic administration of 3-NP produced age-dependent bilateral striatal lesions with a similar neurochemical profile. However, in contrast to the intrastriatal injections, striatal dopaminergic afferent projections were spared. Both freeze-clamp measurements and chemical shift magnetic resonance spectroscopy showed that 3-NP impairs energy metabolism in the striatum in vivo. Microdialysis showed no increase in extracellular glutamate concentrations after systemic administration of 3-NP. The lesions produced by intrastriatal injection or systemic administration of 3-NP were blocked by prior decortication. However, the NMDA antagonist MK-801 did not block the effects of intrastriatal 3-NP, consistent with a non-NMDA excitotoxic mechanism. In contrast to subacute systemic administration of 3-NP, chronic (1 month) administration produced lesions confined to the striatum in which there was relative sparing of NADPH-diaphorase interneurons, consistent with an NMDA excitotoxic process. Chronic administration showed growth-related proliferative changes in dendrites of spiny neurons similar to changes in Huntington's disease (HD). These results are consistent with in vitro studies showing that mild metabolic compromise can selectively activate NMDA receptors while more severe compromise activates both NMDA and non-NMDA receptors. Chronic administration of 3-NP over 1 month produces selective striatal lesions that replicate many of the characteristic histologic and neurochemical features of HD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692009      PMCID: PMC6576392     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  200 in total

1.  Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.

Authors:  R J Carter; L A Lione; T Humby; L Mangiarini; A Mahal; G P Bates; S B Dunnett; A J Morton
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.

Authors:  Isabel Lastres-Becker; María Gómez; Rosario De Miguel; José A. Ramos; Javier Fernández-Ruiz
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

3.  Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation.

Authors:  Francisca Pérez-Severiano; Abel Santamaría; José Pedraza-Chaverri; Omar N Medina-Campos; Camilo Ríos; José Segovia
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

Review 4.  Convergent mechanisms in etiologically-diverse dystonias.

Authors:  Valerie B Thompson; H A Jinnah; Ellen J Hess
Journal:  Expert Opin Ther Targets       Date:  2011-12-03       Impact factor: 6.902

5.  Acute and long-term response of dopamine nigrostriatal synapses to a single, low-dose episode of 3-nitropropionic acid-mediated chemical hypoxia.

Authors:  Cynthia A Crawford; Garnik Akopian; Justin Ring; Michael W Jakowec; Giselle M Petzinger; Julie K Andersen; Philip Vittozzi-Wong; Kristie Wang; Cristal M Farley; Sergios Charntikov; Danut Mitroi; M Flint Beal; Robert Chow; John P Walsh
Journal:  Synapse       Date:  2010-10-08       Impact factor: 2.562

Review 6.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

7.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

8.  Geometric restraint drives on- and off-pathway catalysis by the Escherichia coli menaquinol:fumarate reductase.

Authors:  Thomas M Tomasiak; Tara L Archuleta; Juni Andréll; César Luna-Chávez; Tyler A Davis; Maruf Sarwar; Amy J Ham; W Hayes McDonald; Victoria Yankovskaya; Harry A Stern; Jeffrey N Johnston; Elena Maklashina; Gary Cecchini; Tina M Iverson
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

Review 9.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

10.  Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy.

Authors:  Micaela Johanna Glat; Nadia Stefanova; Gregor Karl Wenning; Daniel Offen
Journal:  J Neural Transm (Vienna)       Date:  2020-02-17       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.